首页|期刊导航|中国药理学通报|基于UFLC-MS/MS及生物信息学探究黄龙止咳口服液治疗咳嗽变异性哮喘的药效物质基础及作用机制

基于UFLC-MS/MS及生物信息学探究黄龙止咳口服液治疗咳嗽变异性哮喘的药效物质基础及作用机制OA

The pharmacodynamic material basis and mechanism of Huanglong cough oral liquid in treating cough variant asthma via UFLC-MS/MS and bioinformatics

中文摘要英文摘要

目的 探讨黄龙止咳口服液(Huanglong cough oral liq-uid,HL)治疗咳嗽变异性哮喘(cough variant asthma,CVA)的药效物质基础及作用机制.方法 通过卵清蛋白(ovalbu-min,OVA)致敏构建 CVA 大鼠模型,采用 UFLC-MS/MS及Elisa法分别检测灌胃给予HL后d 1、7、14大鼠血清中麻黄碱等9种成分及干扰素γ(interferon-γ,IFN-γ)、白细胞介素4(interleukin-4,IL-4)和肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)的含量变化.基于生物信息学筛选出HL的潜在治疗靶点,苏木精-伊红染色法(hematoxylin-eosin staining,HE)染色观察肺组织病理变化情况,利用辣椒素及乙酰胆碱激发观察HL及有效成分干预前后大鼠咳嗽次数、气道高反应性(airway hyperresponsiveness,AHR)检测指标气道阻力(enhanced pause,Penh)的变化,进一步采用 RT-qPCR 及Western blot检测靶点基因及蛋白的表达.结果 HL 9种成分的含量随给药时间延长呈上升趋势,并于给药d 7达到稳态血药浓度.HL可剂量依赖性地逆转CVA大鼠血清中IFN-γ、IL-4及TNF-α的异常变化,高、中剂量组于给药d 7、14趋近于正常组.生信分析筛选出瞬时受体电位锚蛋白1(transient receptor potential ankyrin 1,TRPA1)、瞬时受体电位香草酸1(transient receptor vanilloid,TRPV1)、Erb-B2受体酪氨酸激酶2(Erb-B2 receptor tyrosine kinase 2,ERBB2)、一氧化氮合酶2(nitric oxide synthase 2,NOS2)、胞浆磷脂酶A2-IVA(cytoplasmic phospholipase A2-IVA,PLA2G4A)和前列环素I2受体(prostaglandin I2 receptor,PTGIR)6个最相关的潜在靶点.HL及9种成分可剂量依赖性地调控除TRPV1外5种潜在靶点基因及蛋白的表达来减少咳嗽次数和抑制气道高反应性从而缓解嗽变异性哮喘,且HL的治疗效果优于9种成分.结论 麻黄碱等9种成分可能是HL治疗CVA的药效物质,HL的血药浓度与药物效应不是绝对的正比关系,HL的治疗作用与参与免疫炎症反应调控密切相关.

Aim To explore the pharmacodynamic material basis and mechanism of action of Huanglong cough oral liquid(HL)in treating cough variant asthma(CVA).Methods CVA rats model was estab-lished using ovalbumin(OVA)sensitization.Ultra-fast liquid chromatography tandem mass spectrometry(UFLC-MS/MS)and enzyme-linked immunosorbent assay(Elisa)were used to detect changes in serum levels of ephedrine and eight other components,as well as interferon-γ(IFN-γ),interleukin-4(IL-4),and tumor necrosis factor-α(TNF-α)on day 1,7,and 14 after intragastric administration of HL.Bioinformat-ics was employed to screen for potential therapeutic tar-gets of HL.Hematoxylin-eosin(HE)staining was used to observe the pathological changes in lung tis-sue.Capsaicin and acetylcholine challenges were ap-plied to observe changes in cough frequency and the airway hyperresponsiveness(AHR)indicator en-hanced pause(Penh)before and after HL and active component intervention.RT-qPCR and Western blot were further used to detect the expression of target genes and proteins.Results The serum concentra-tions of the 9 HL components showed an increasing trend over time,reaching a steady-state concentration by d 7 of administration.HL dose-dependently re-versed the abnormal changes in serum IFN-γ,IL-4,and TNF-α levels in CVA rats,with the middle-and high-HL groups approximating those of the normal group by day 7 and 14.Bioinformatics analysis identi-fied six highly relevant potential targets:transient re-ceptor potential ankyrin 1(TRPA1),transient recep-tor potential vanilloid 1(TRPV1),Erb-B2 Receptor Tyrosine Kinase 2(ERBB2),Nitric Oxide Synthase 2(NOS2),cytoplasmic phospholipase A2-IVA(PLA2G4A),and Prostaglandin I2 Receptor(PT-GIR).HL and its nine components dose-dependently regulated the gene and protein expression of five poten-tial targets(excluding TRPV1),thereby reducing cough frequency and inhibiting AHR to alleviate CVA.The therapeutic effect of HL was superior to that of the individual nine components.Conclusions 9 components including ephedrine are likely the pharma-codynamic material basis of HL for treating CVA.HL exhibits a non-linear concentration-effect relationship,characteristic of multi-component herbal therapeutics.The therapeutic effect of HL is closely related to the regulation of immune-inflammatory responses.

田昊林;吴晓;王楠;刘峥

南京中医药大学附属南京中医院,江苏 南京 210022南京中医药大学附属南京中医院,江苏 南京 210022南京中医药大学中西医结合学院,江苏 南京 210023南京中医药大学附属南京中医院,江苏 南京 210022

医药卫生

黄龙止咳口服液咳嗽变异性哮喘UFLC-MS/MS药效成分生物信息学作用机制

Huanglong cough oral liquidcough vari-ant asthmaUFLC-MS/MSpharmacodynamic compo-nentsbioinformaticsmechanism of action

《中国药理学通报》 2026 (3)

574-583,10

国家自然科学基金资助项目(No 81904253)江苏省中药骨干人才高级研修项目(No SZYGGYC-LZ)2024年度江苏省基础研究专项资金(自然科学基金)配套项目(No PT20240406)南京中医药大学自然科学基金项目(No XZR2024034)南京市医学科技发展项目(No YKK17156)2024年江苏省研究生实践创新计划(No 925)

10.12360/CPB202504069

评论